Order Article Reprints

Raynes G, Stares M, Low S, Haron D, Sarwar H, Abhi D, Barrie C, Laird B, Caledonian Cachexia Collaborative, Phillips I, et al. Immune-Related Adverse Events, Biomarkers of Systemic Inflammation, and Survival Outcomes in Patients Receiving Pembrolizumab for Non-Small-Cell Lung Cancer. Cancers. 2023; 15(23):5502. https://doi.org/10.3390/cancers15235502

Raynes, George, Mark Stares, Samantha Low, Dhania Haron, Hussain Sarwar, Dhruv Abhi, Colin Barrie, Barry Laird, Caledonian Cachexia Collaborative, Iain Phillips, and et al. 2023. "Immune-Related Adverse Events, Biomarkers of Systemic Inflammation, and Survival Outcomes in Patients Receiving Pembrolizumab for Non-Small-Cell Lung Cancer" Cancers 15, no. 23: 5502. https://doi.org/10.3390/cancers15235502

Raynes, G., Stares, M., Low, S., Haron, D., Sarwar, H., Abhi, D., Barrie, C., Laird, B., Caledonian Cachexia Collaborative, Phillips, I., & MacKean, M. (2023). Immune-Related Adverse Events, Biomarkers of Systemic Inflammation, and Survival Outcomes in Patients Receiving Pembrolizumab for Non-Small-Cell Lung Cancer. Cancers, 15(23), 5502. https://doi.org/10.3390/cancers15235502